Abstract
Various grades of adverse events are associated with sorafenib and have recently been considered as a surrogate of response in patients with advanced hepatocellular carcinoma. The aim of this prospective study was to measure the efficacy of a sorafenib dose reduction regimen, adjusted on patient's tolerability, and aimed at increasing the exposure to the drug.
Lingua originale | English |
---|---|
pagine (da-a) | N/A-N/A |
Rivista | Liver International |
DOI | |
Stato di pubblicazione | Pubblicato - 2015 |
Keywords
- adverse events
- hepatocellular carcinoma
- sorafenib
- tolerable adverse events protocol
- toxicity
- tumor response